Protocol to investigate the effect of cyclo-oxygenase (COX)-2 inhibition on reducing central sensitisation of pain in osteoarthritis

ISRCTN ISRCTN36231538
DOI https://doi.org/10.1186/ISRCTN36231538
EudraCT/CTIS number 2006-000395-32
Secondary identifying numbers N/A
Submission date
28/07/2008
Registration date
30/09/2008
Last edited
17/04/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Ernest Choy
Scientific

Weston Education Centre
10 Cutcombe Road
London
SE5 9RJ
United Kingdom

Phone +44 (0)207 848 5206
Email kch-tr.kms-ctu@nhs.net

Study information

Study designNon-randomised controlled trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleProtocol to investigate the effect of cyclo-oxygenase (COX)-2 inhibition on reducing central sensitisation of pain in osteoarthritis
Study objectivesThis study aims to assess whether cyclo-oxygenase (COX)-2 selective inhibition by etoricoxib reduces central sensitisation of pain in patients with chronic osteoarthritis (OA) using functional magnetic resonance imaging (fMRI) scan.
Ethics approval(s)St Thomas' Hospital Research Ethics Committee. Date of approval: 23/03/2006
Health condition(s) or problem(s) studiedOsteoarthritis
Intervention16 patients will be recruited from the Rheumatology Outpatient Clinic of King's College Hospital. 16 healthy controls will be recruited from the staff and student population at King's College London (32 participants in total).

Interventions: Etoricoxib (oral) 60 mg daily for 2 weeks vs no treatment
Intervention typeOther
Primary outcome measure1. Pressure pain thresholds (PPTs) will be determined using a pressure algometer. Patients will be asked to indicate the site of ongoing pain on a mannequin. This site and the homologous contralateral site will be marked with a pen and noted in the patient record. The pressure pain level will be assessed twice at each site (rate of stimulus increase 50 kPa; probe area 1 cm2) and the average of two perception levels will be calculated as the individual PPT for that site.
2. Functional MRI (fMRI) will be used to assess brain responses to a standardised pain provocation produced by pressure delivered to a non fibromyalgia syndrome (FMS) pressure point of the knee. The fMRI evaluation will involve multiple 8 min scans using an event-related design. Pressure stimuli of 2.5 seconds duration will be delivered to the right knee at random intervals varying between 10 and 20 seconds. This will then be repeated for the left knee. The control group will have only one scan.

Assessments will be carried out at baseline and after 2 weeks of treatment with etoricoxib for OA patients. Healthy controls will only complete baseline assessments.
Secondary outcome measures1. Mechanoreceptive function
2. Sensitivity to stimulus invoked pain

Assessments will be carried out at baseline and after 2 weeks of treatment with etoricoxib for OA patients. Healthy controls will only complete baseline assessments.
Overall study start date01/09/2008
Completion date01/03/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants32
Key inclusion criteriaFor all participants:
1. Both males and females, age >18 years old
2. Those who are right handed
3. Signed informed consent

For participants with OA:
1. Patients with ACR criteria defined OA of the knee
2. Radiological OA
3. Patients who have been suffering from pain for more than 1 year
Key exclusion criteria1. History of hypersensitivity to the active substance or to any of the excipients
2. Active peptic ulceration or active gastro-intestinal (GI) bleeding
3. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors
4. Pregnancy and lactation
5. Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score >=10)
6. Estimated renal creatinine clearance <30 ml/min
7. Inflammatory bowel disease
8. Congestive heart failure (New York Heart Association [NYHA] II-IV)
9. Patients with hypertension whose blood pressure has not been adequately controlled
Date of first enrolment01/09/2008
Date of final enrolment01/03/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Weston Education Centre
London
SE5 9RJ
United Kingdom

Sponsor information

Kings College London (UK)
University/education

Strand
London
WC2R 2LS
England
United Kingdom

Phone +44 (0)20 7836 5454
Email kch-tr.kms-ctu@nhs.net
Website http://www.kcl.ac.uk
ROR logo "ROR" https://ror.org/0220mzb33

Funders

Funder type

Industry

Merck Sharp & Dohme Ltd (MSD) (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results No No

Editorial Notes

17/04/2019: A EudraCT link has been added to the basic results (scientific)
26/08/2016: No publications found, verifying study status with principal investigator